Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of the Safety, Tolerability, and Immune Effects of Nasal Protollin in Subjects With Early Symptomatic Alzheimer's Disease

NCT07187141 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT07187141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07187141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of the Safety, Tolerability, and Immune Effects of Nasal Protollin in Subjects With Early Symptomatic Alzheimer's Disease
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 1
Overall status
Completed
Start date
November 18, 2021
Completion date
February 21, 2023
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease (ad)